Skip to main content
SpringerLink
Log in

Metabolism of digitoxin in man and its modification by spironolactone

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The effect of spironolactone on the metabolism of intravenously administered3H-digitoxin (80 µCi) was investigated in eight patients. In three of them the labelled glycoside was given on a second occasion after spironolactone treatment had been discontinued for at least 65 days. Of total urinary radioactivity 79 % was unaltered drug and 12 % consisted of water soluble compounds. No digitoxigenin or digoxigenin and only trace amounts (<2 %) of digoxin and the bis- and monoglycosides of digoxigenin were found. After spironolactone total urinary radioactivity was unchanged but the fraction eliminated as unchanged digitoxin fell from 79 to 66 % and the water soluble compounds increased from 12 to 26 % (p<0.05). In addition spironolactone caused a 20 % reduction in the half-life of serum radioactivity (p<0.01) and a 16 % reduction in the volume of distribution (p<0.05). Induction of hepatic enzymes by spironolactone is proposed to explain the alteration in the metabolism of digitoxin in man. Both the altered metabolic pattern and the reduction in the volume of distribution appear to contribute to the reduction in half-life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abshagen, U., Rennekamp, H., Kuhlmann, J.: Pharmacokinetics of 4‴-methyldigoxin after pretreatment with spironolactone in man. Naunyn Schmiedeberg's Arch. Pharmacol. Suppl.285, R 1 (1974)

  2. Anton, A.H., Sayre, D.F.: A study of the factors effecting the aluminium oxide-trihydroxyindole procedure for the analysis of catecholamines. J. Pharmacol. exp. Ther.138 360–375 (1962)

    Google Scholar 

  3. Ashley, J.J., Brown, B.T., Okita, G.T., Wright, S.E.: The metabolites of cardiac glycosides in human urine. J. biol. Chem.232 315–322 (1958)

    Google Scholar 

  4. Brown, P., Brüschweiler, F., Pettit, G.R., Reichstein, T.: Field ionization mass spectrometry. III: cardenolides. Org. Mass. Spectrum5 573–597 (1971)

    Google Scholar 

  5. Buck, S.H., Lage, G.L.: Possible mechanism of the prevention of digitoxin toxicity by spironolactone in the mouse. Arch. int. Pharmacodyn.189 192–197 (1971)

    Google Scholar 

  6. Castle, H.C., Lage, G.L.: Excretion of3H-digitoxin and its metabolites following spironolactone pretreatment in rats. Drug Metab. Dis.1 590–597 (1973)

    Google Scholar 

  7. Doherty, J.E., Perkins, W.H., Mitchell, G.K.: Tritiated digoxin studies in human subjects. Arch. int. Med.108 531–539 (1961)

    Google Scholar 

  8. Doherty, J.E., Hall, W.H., Murphy, M.L., Beard, O.W.: New information regarding digitalis metabolism. Chest59 433–437 (1971)

    Google Scholar 

  9. Douglas, J.G., Hollifield, J.W., Liddle, G.W.: Treatment of low-renin essential hypertension. J. Amer. med. Ass.227 518–527 (1974)

    Google Scholar 

  10. Falkner, F.C., Frölich, J.C., Watson, J.T.: Mass spectrometry of the trimethylsilyl derivatives of some cardiac aglycones and monoglycosides. Org. Mass. Spectrum7 141–153 (1973)

    Google Scholar 

  11. Hamrick, M.E., Zampaglione, N.G., Stripp, B., Gilette, J.R.: Investigation of the effect of methyltestosterone, cortisone and spironolactone on the hepatic microsomal mixed function oxydase system in male and female rats. Biochem. Pharmacol.22 293–310 (1973)

    Google Scholar 

  12. Jelliffe, R.W., Buell, J., Kalaba, R., Sridhar, R., Rockwell, R., Wagner, J.G.: An improved method of digitoxin therapy. Ann. int. Med.72 453–464 (1970)

    Google Scholar 

  13. Jelliffe, R.W.: Discussion of the paper: Some aspects of the distribution and disposition of digitoxin in man (Lukas, D.S.). Ann. N.Y. Acad. Sci.179 359–361 (1971)

    Google Scholar 

  14. Katzung, B.G., Meyers, F.H.: Biotransformation of digitoxin in the dog. J. Pharmacol. exp. Ther.154 575–580 (1966)

    Google Scholar 

  15. Kuschinsky, K.: Bestimmung der Eiweißbindung verschiedener Herzglykoside mittels Sephadex®-Gelfiltration. Naunyn Schmiedeberg's Arch. Pharmak. exp. Path.259 394–399 (1968)

    Google Scholar 

  16. Lage, G.L., Spratt, J.L.:3H-Digoxin metabolism by adult male rat tissuesin vitro. J. Pharmacol. exp. Ther.149 248–256 (1965)

    Google Scholar 

  17. Lahrtz, Hg., Reinold, H.M., Van Zwieten, P.A.: Serumkonzentration und Ausscheidung von3H-Digitoxin beim Menschen unter normalen und pathologischen Bedingungen. Klin. Wschr.47 695–700 (1969)

    Google Scholar 

  18. Lukas, D.S.: Some aspects of the distribution and disposition of digitoxin in man. Ann. N. Y. Acad. Sci.179 338–359 (1971)

    Google Scholar 

  19. Lukas, D.S., DeMartino, A.G.: Binding of digitoxin and some related cardenolides to human plasma proteins. J. clin. Invest.48 1041–1053 (1969)

    Google Scholar 

  20. Lukas, D.S., Peterson, R.E.: Double isotope dilution derivative assay of digitoxin in plasma, urine and stool of patients maintained on the drug. J. clin. Invest.45 782–795 (1966)

    Google Scholar 

  21. Okita, G.T., Kelsey, F.E., Talso, P.J., Smith, L.B., Geiling, E.M.K.: Studies on the renal excretion of radioactive digitoxin in human subjects with cardiac failure. Circulation7 161–168 (1953)

    Google Scholar 

  22. Repke, K.: Die Bis- und Mono-digitoxoside des Digitoxigenins und Digoxigenins: Metaboliten des Digitoxins. Naunyn Schmiedeberg's Arch. exp. Path. Pharm.237 155–170 (1959)

    Google Scholar 

  23. Repke, K.: Metabolism of cardiac glycosides. Proc. First. Internat. Pharmacol. Mtg., Stockholm 1961,3, 47–73 Oxford: Pergamon Press 1963

    Google Scholar 

  24. Sadee, W., Abshagen, U., Finn, C., Rietbrock, N.: Conversion of spironolactone to canrenone and disposition kinetics of spironolactone and canrenoate-potassium in rats. Naunyn Schmiedeberg's Arch. Pharmacol.283 303–318 (1974)

    Google Scholar 

  25. Selye, H., Krajny, M., Savoie, L.: Digitoxin poisoning: prevention by spironolactone. Science164 842–843 (1969)

    Google Scholar 

  26. Solomon, H.M., Reich, S., Spirt, N., Abrams, W.B.: Interactions between digitoxin and other drugsin vitro andin vivo. Ann. N.Y. Acad. Sci.179 362–368 (1971)

    Google Scholar 

  27. Solymoss, B., Classen, H.G., Varga, S.: Increased hepatic microsomal activity induced by spironolactone and other steroids. Proc. Soc. exp. Biol. (N.Y.)132 940–942 (1969)

    Google Scholar 

  28. Solymoss, B., Toth, S., Varga, S., Selye, H.: Protection by spironolactone and oxandrolone against chronic digitoxin or indomethacin intoxication. Toxicol. appl. Pharmacol.18 586–592 (1971)

    Google Scholar 

  29. Stahl, E.: Thin-layer chromatography, p. 870, 2nd ed., Berlin, Heidelberg, New York: Springer-Verlag 1969

    Google Scholar 

  30. Steiness, E.: Renal tubular secretion of digoxin. Circulation50 103–107 (1974)

    Google Scholar 

  31. Storstein, L.: Studies on digitalis. I. Renal excretion of digitoxin and its cardioactive metabolites. Clin. Pharmacol. Ther.16 14–24 (1974)

    Google Scholar 

  32. Stripp, B., Hamrick, M.E., Zampaglione, N.G., Gilette, J.R.: The effect of spironolactone on drug metabolism by hepatic microsomes. J. Pharmacol. exp. Ther.176 766–771 (1971)

    Google Scholar 

  33. Taylor, S.A., Rawlins, M.D., Smith, S.E.: Spironolactone — a weak inducer in man. J. Pharm. Pharmacol.24 578–579 (1972)

    Google Scholar 

  34. Vöhringer, H.F., Rietbrock, N.: Metabolism and excretion of digitoxin in man. Clin. Pharmacol. Ther.16 796–806 (1974)

    Google Scholar 

  35. Watson, J.T., Pelster, T.R., Sweetman, B.J., Frölich, J.C., Oates, J.A.: A display oriented data system for multiple ion detection with gas chromatography-mass spectrometry in quantifying biomedically important compounds. Anal. Chem.45 2071–2078 (1973)

    Google Scholar 

  36. Wirth, K.E., Frölich, J.C.: Effect of spironolactone on excretion of3H-digoxin and its metabolites in rats. Europ. J. Pharmacol.29 43–51 (1974)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine and Pharmacology, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA

    K. E. Wirth, J. C. Frölich, J. W. Hollifield, F. C. Falkner, B. S. Sweetman & J. A. Oates

  2. Pharmakologisches Institut der Univ., Moorenstraße 5, D - 4000, Düsseldorf, Federal Republic of Germany

    K. E. Wirth

Authors
  1. K. E. Wirth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. C. Frölich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. W. Hollifield
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. C. Falkner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. S. Sweetman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. A. Oates
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Fellow of the Paul Martini-Stiftung, Frankfurt/Main, Germany

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wirth, K.E., Frölich, J.C., Hollifield, J.W. et al. Metabolism of digitoxin in man and its modification by spironolactone. Eur J Clin Pharmacol 9, 345–354 (1976). https://doi.org/10.1007/BF00606547

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00606547

Key words

Search

Navigation